springworks therapeutics gomekli

SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved GOMEKLI, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.

PMLiVE · 10h

FDA approves SpringWorks Therapeutics’ Gomekli to treat neurofibromatosis type 1

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 people in the US.

Hosted on MSN · 1d

US FDA approves SpringWorks' genetic disorder drug

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare genetic disorder, which causes tumors to grow in the tissue that covers nerves throughout the body.

Business Insider · 2d

SpringWorks Therapeutics confirms FDA approval of Gomekli

SpringWorks Therapeutics (SWTX) announced that the U.S. FDA has approved Gomekli, SpringWorks’ MEK inhibitor, for the treatment of adult and

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

FiercePharma1d

Amid takeover talk, SpringWorks scores FDA nod for rare genetic disease treatment Gomekli

Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...

GlobalData on MSN1d

FDA approves Gomekli as first neurofibromatosis drug for adults

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

10h

SpringWorks Therapeutics price target raised to $87 from $65 at BofA

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...

Pharm Exec1d

FDA Approves SpringWorks Therapeutics’ Gomekli for Neurofibromatosis Type 1, Symptomatic Plexiform Neurofibromas

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

1don MSN

SpringWorks shares rise on FDA nod for GOMEKLI

Shares of SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) climbed 2.7%, building on a previous gain of 2%, following the FDA ...

FDA approves new genetic disorder drug

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...

BioSpace1d

SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration’s approval for Gomekli ...

Hartford Business1d

FDA approves CT drugmaker’s therapy for rare cancer tumors

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results